메뉴 건너뛰기




Volumn 112, Issue 12, 2015, Pages 1888-1894

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Author keywords

anti EGFR monoclonal antibodies; BRAF V600E mutation; metastatic colorectal cancer; predictive biomarkers

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

EID: 84930872726     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.173     Document Type: Article
Times cited : (267)

References (33)
  • 1
    • 34047248571 scopus 로고    scopus 로고
    • Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
    • Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
    • (2007) Cancer Res , vol.67 , pp. 2643-2648
    • Benvenuti, S.1    Sartore-Bianchi, A.2    Di Nicolantonio, F.3    Zanon, C.4    Moroni, M.5    Veronese, S.6    Siena, S.7    Bardelli, A.8
  • 2
    • 84862026304 scopus 로고    scopus 로고
    • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    • Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C-H (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466-1475.
    • (2012) Eur J Cancer , vol.48 , pp. 1466-1475
    • Bokemeyer, C.1    Cutsem, E.V.2    Rougier, P.3    Ciardiello, F.4    Heeger, S.5    Schlichting, M.6    Celik, I.7    Köhne, C.-H.8
  • 9
    • 77955382172 scopus 로고    scopus 로고
    • Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal
    • Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA (2010) Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11: 85.
    • (2010) Trials , vol.11 , pp. 85
    • Kent, D.M.1    Rothwell, P.M.2    Ioannidis, J.P.3    Altman, D.G.4    Hayward, R.A.5
  • 21
    • 11844302840 scopus 로고    scopus 로고
    • Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation
    • Rothwell PM (2005) Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365: 176-186.
    • (2005) Lancet , vol.365 , pp. 176-186
    • Rothwell, P.M.1
  • 22
    • 84867298938 scopus 로고    scopus 로고
    • The prognostic value of BRAF mutation in colorectal cancer and melanoma: A systematic review and meta-analysis
    • Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7: e47054.
    • (2012) PLoS One , vol.7 , pp. e47054
    • Safaee Ardekani, G.1    Jafarnejad, S.M.2    Tan, L.3    Saeedi, A.4    Li, G.5
  • 25
    • 70449420123 scopus 로고    scopus 로고
    • Use of archived specimens in evaluation of prognostic and predictive biomarkers
    • Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101: 1446-1452.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1446-1452
    • Simon, R.M.1    Paik, S.2    Hayes, D.F.3
  • 27
    • 84929141867 scopus 로고    scopus 로고
    • Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized controlled trials
    • Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann Oncol 26: 13-21.
    • (2015) Ann Oncol , vol.26 , pp. 13-21
    • Sorich, M.J.1    Wiese, M.D.2    Rowland, A.3    Kichenadasse, G.4    McKinnon, R.A.5    Karapetis, C.S.6
  • 28
    • 77951082212 scopus 로고    scopus 로고
    • Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses
    • Sun X, Briel M, Walter SD, Guyatt GH (2010) Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340: c117.
    • (2010) BMJ , vol.340 , pp. c117
    • Sun, X.1    Briel, M.2    Walter, S.D.3    Guyatt, G.H.4
  • 29
    • 84903301924 scopus 로고    scopus 로고
    • The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
    • Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M (2014) The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53: 852-864.
    • (2014) Acta Oncol , vol.53 , pp. 852-864
    • Therkildsen, C.1    Bergmann, T.K.2    Henrichsen-Schnack, T.3    Ladelund, S.4    Nilbert, M.5
  • 30
    • 67649652208 scopus 로고    scopus 로고
    • BRAF mutation in metastatic colorectal cancer
    • Tol J, Nagtegaal ID, Punt CJA (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99.
    • (2009) N Engl J Med , vol.361 , pp. 98-99
    • Tol, J.1    Nagtegaal, I.D.2    Punt, C.J.A.3
  • 31
    • 84880022343 scopus 로고    scopus 로고
    • Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis
    • Xu Q, Xu AT, Zhu MM, Tong JL, Xu XT, Ran ZH (2013) Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Digest Dis 14: 409-416.
    • (2013) J Digest Dis , vol.14 , pp. 409-416
    • Xu, Q.1    Xu, A.T.2    Zhu, M.M.3    Tong, J.L.4    Xu, X.T.5    Ran, Z.H.6
  • 32
    • 84881543270 scopus 로고    scopus 로고
    • Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
    • Yang Z-Y, Wu X-Y, Huang Y-F, Di M-Y, Zheng D-Y, Chen J-Z, Ding H, Mao C, Tang J-L (2013) Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 133: 1914-1925.
    • (2013) Int J Cancer , vol.133 , pp. 1914-1925
    • Yang, Z.-Y.1    Wu, X.-Y.2    Huang, Y.-F.3    Di, M.-Y.4    Zheng, D.-Y.5    Chen, J.-Z.6    Ding, H.7    Mao, C.8    Tang, J.-L.9
  • 33
    • 84878901220 scopus 로고    scopus 로고
    • The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: A meta-analysis
    • Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L, Wang JP (2013) The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8: e65995.
    • (2013) PLoS One , vol.8 , pp. e65995
    • Yuan, Z.X.1    Wang, X.Y.2    Qin, Q.Y.3    Chen, D.F.4    Zhong, Q.H.5    Wang, L.6    Wang, J.P.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.